Modulating the progression in IgA nephropathy.
IgA nephropathy affects almost 1% of the population and yet the diagnosis is often missed. This significant kidney disease is often progressive with 25% of the patients going on to end-stage kidney disease over the course of 25 years. This minireview describes the clinical presentations in children and young adults. Therapeutic options are discussed including angiotensin-converting enzyme blockade, steroids, cytotoxics, tonsillectomy, fish oil, vitamin E, singly or in combination, in order to modulate the rate of progression.
Chan
James C M
JC
University of Vermont and the Barbara Bush Children's Hospital, Maine Medical Center, Portland, Me 04102-3175, USA. chanj@suscom-maine.net
Trachtman
Howard
H
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D018450:Disease Progression; D005395:Fish Oils / Q000627:therapeutic use; D005922:Glomerulonephritis, IGA / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D014068:Tonsillectomy; D014810:Vitamin E / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D005395:Fish Oils; D014810:Vitamin E